Clinical trial
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With…
NCT00286247 · Introgen Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00286247 |
|---|---|
| Title | Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer |
| Lead sponsor | Introgen Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Locally Advanced Breast Cancer (LABC) |
| Intervention type | Genetic |
| Interventions | INGN 201 |
| Enrollment | 60 |
| First posted | Feb 3, 2006 |
| Last update posted | Apr 1, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: